Rapid emotional recovery of breast-cancer survivors surprises researchers

December 21, 2005

Contrary to psychologists' expectations, breast cancer survivors don't experience an extended emotional crisis after their treatment regimens end, according to a new study by researchers at Washington University School of Medicine in St. Louis. The study appears in the December issue of Supportive Care in Cancer.

"We thought we'd find that women do worse psychologically after treatment," says Washington University psychologist, Teresa L. Deshields, Ph.D., assistant professor of medicine. "That's the clinical lore. After all, many of the patients referred to us are the ones struggling at the end of treatment. But our study shows that within two weeks most women adjust very well to survivorship."

The research team surveyed 94 women drawn from patients of the radiation oncology practice at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital. The women, averaging 55 years of age, had stage 0, I, II or III breast cancer and at the start of the study were completing the last of a six- to seven-week course of daily radiation treatments.

The women were surveyed five times: on their last day of radiation treatment, two weeks later, several days before their first follow-up appointment (four to six weeks post-treatment) and at three and six months. The survey measured patients' depressive symptoms and quality of life (the quality of life measurement quantifies a set of attributes that include physical, social/family, emotional and functional well-being, and breast-cancer-specific concerns). For the group of breast-cancer survivors, the average score for indications of depression was heightened at the end of treatment compared to a group of healthy men and women. A higher score on the depression index indicates more severe depressive symptoms.

The measure of depressive symptoms dropped significantly after treatment, reaching a low two weeks later and staying fairly stable to the six-month time point. The average score for the breast-cancer survivors was similar to the scores of healthy men and women at the two-week checkpoint.

The average quality of life score for the breast-cancer survivors was low at the end of treatment when tested using a scale that captures important breast-cancer-specific issues such as feelings of femininity or self-consciousness about clothes. In this measurement, lower scores indicate worse quality of life.

The average patient's score rose significantly over the survey period. At the two-week mark the average quality-of-life score for these breast-cancer survivors was near the average score of a control group that consisted of other breast-cancer patients and reached and then exceeded that number at the time of follow-up and later times.

"Previous studies had never looked at breast-cancer survivors so soon after treatment, and we were surprised that most improvement happened so quickly," says Deshields, who directs Psycho-Oncology Services at the Siteman Center. "There's a concept called resiliency, the notion that people can withstand a lot and come through fine. Our largest patient group by far was these resilient patients who never experienced clinically significant depressive symptoms."

The study demonstrated that at each of the survey time points 75 percent of the patients were not clinically depressed. Some patients temporarily experienced symptoms of clinical depression at one or more time points, but only 6 percent stayed depressed throughout the study.

Deshields believes there are some important messages in the study for oncologists. One is that they can reassure patients at the end of treatment that their quality of life will improve quickly and any depressive feelings are likely to dissipate soon.

On the other hand, while most patients do bounce back after treatment, the study also found a small group who stayed depressed. Deshields says if patients don't get better quickly, their doctors should be concerned.

Of those patients who do experience serious emotional difficulties after treatment, their troubles can stem from the sudden loss of medical oversight and the support of family and friends. "When treatment ends, suddenly patients are let go--that's very hard for some people," Deshields says. "Often patients try to reintegrate into their usual lives. Inevitably, they find that life is different--they can't go back to where they were before treatment. They have to find a new normal."

Deshields's next study will use a new pain inventory her group developed to investigate cancer pain. The team will look at clusters of beliefs about cancer pain and determine how they affect cancer patients' tendency to report pain to their doctors.
Deshields T, Tibbs T, Fan M-Y, Bayer L, Taylor M, Fisher E. Ending treatment: the course of emotional adjustment and quality of life among breast cancer survivors immediately following radiation therapy. Supportive Care in Cancer, 2005 Dec;13(12):1018-1026.

Funding from an Alvin J. Siteman Cancer Center Research Development Grant Award supported this research.

Washington University School of Medicine's full-time and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked third in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Siteman Cancer Center is the only NCI-designated Comprehensive Cancer Center within a 200-mile radius of St. Louis. Siteman Cancer Center is composed of the combined cancer research and treatment programs of Barnes-Jewish Hospital and Washington University School of Medicine.

View online: http://mednews.wustl.edu/news/page/normal/6327.html?emailID=7562

Washington University School of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.